CollaMedix Inc., a biotech startup based in Shaker Heights, has developed new technology in collaboration with Case Western Reserve University and University Hospitals Cleveland Medical Center. This technology offers a promising potential solution to women's pelvic disorders, such as stress urinary incontinence and pelvic organ prolapse.

CollaMedix has created a medical device known as CollaSling, which aims to treat stress urinary incontinence in women—urine leakage coinciding with laughing, coughing, sneezing, lifting and exercise—by using proprietary collagen-based materials to provide structural support to human tissue.

“This common condition affects both the young and elderly, yet current treatments are ineffective and unsafe,” said Subba Shankar, the company’s chief technology officer. “Our technology will allow more women to fully engage in all of life’s activities without hesitation, avoiding the withdrawal, isolation and depression that they presently endure.”

Collamedix has recently reached an exclusive licensing agreement with the Case Western Reserve Technology Transfer Office. This will allow the company the chance to secure additional funding.